Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Kevin D. Freeman currently holds 55,269 shares of GALECTIN THERAPEUTICS INC (GALT), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Kevin D. Freeman has been a net buyer of GALT stock. They have purchased $350.7K and sold $0 worth of shares.
Kevin D. Freeman's most recent insider trade was on Dec 23, 2025, when they purchased 5,500 shares at $3.55 per share.
Kevin D. Freeman serves as Executive at GALECTIN THERAPEUTICS INC (GALT). They have executed 39 insider transactions totaling $350.7K over their tenure at the company.
Kevin D. Freeman holds the position of Executive at GALECTIN THERAPEUTICS INC, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 13 years and currently hold a stake valued at $0.
Kevin D. Freeman has shown a buying trading pattern, with $350.7K in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Kevin D. Freeman was on May 31, 2019, when they purchased $33.0K worth of GALT shares. This transaction involved 7,710 shares at $4.28 per share.
Kevin D. Freeman currently owns 55,269 shares of GALECTIN THERAPEUTICS INC (GALT), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Kevin D. Freeman's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Kevin D. Freeman has 39 Form 4 filings on record as an insider at GALECTIN THERAPEUTICS INC.
Set alerts for Kevin D. Freeman and 40,000+ other insiders.